Gender representation in drug development studies for diabetes mellitus: A systematic review
-
AuthorsHerskind A.E.J.; Norgaard B.
-
TypeOriginal research
-
JournalDiabetes and Metabolic Syndrome: Clinical Research and Reviews
-
Publication Date2023
-
Abstract
Background: During the last 20 years, the prevalence of diabetes mellitus (DM) has increased drastically, and so has the number of associated medicine and drug development studies. Despite knowing that men and women respond differently to DM medicines, biological gender differences still tend not to be prioritized during medicine development.
Objective(s): This study examined gender representation in medicine development studies for DM.
Method(s): We conducted a systematic review, and in February 2022, we searched EMBASE (Excerpta Medica Database), MEDLINE (Medical Literature Analysis and Retrieval System Online) and PubMed using a block search strategy. Randomized controlled studies (RCTs) including people diagnosed with DM (any type) aged 18-65 years were included. The Consolidated Standards of Reporting Trial 2010 checklist was applied to assess the studies’ reported quality. The results are presented in a narrative synthesis.